{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-032048","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2021-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.918192+00:00","generated_at":"2026-06-27T23:51:21.148409+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immix Biopharma closes IPO of 4.2M shares at $5.00/share for $21M gross proceeds","bullets":["IPO closed Dec 20, 2021; shares began trading on Nasdaq Dec 16 under IMMX.","Gross proceeds $21M; underwriters have 45-day option for up to 630K additional shares.","Net proceeds to fund IMX-110 Phase 2a trial in soft tissue sarcoma and combination trial.","Also fund IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease).","Filed amended charter and bylaws in connection with IPO closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-032048","json":"https://secwatch.observer/filing/0001493152-21-032048.json","markdown":"https://secwatch.observer/filing/0001493152-21-032048.md","text":"https://secwatch.observer/filing/0001493152-21-032048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315221032048/0001493152-21-032048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315221032048/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:51:21.148409+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}